HEALTH● LOW1h ago · Oct 6, 2026, 2:53 PM
BridgeBio nabs Priority Review for infigratinib for achondroplasia
Seeking Alpha Tech · global
BridgeBio has received Priority Review for its drug infigratinib for achondroplasia, indicating a faster review process for a potentially important treatment. This could accelerate access to a new therapy for a genetic condition.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH23m agoRussia denies imposing anti-plague measures after death of workerVanguard NigeriaHEALTH50m agoBacteria in cocktail: Food Safety dept. files case against outlet in Keralam’s KannurThe HinduHEALTH59m agoKenya reports first-ever Ebola death after patient returns from DR CongoFrance 24 [en]HEALTH1h agoI’ve been in therapy since COVID – Chris RockVanguard Nigeria